title: Persistent high mortality in advanced HIV/TB despite appropriate antiretroviral and antitubercular therapy: an emerging challenge.
abstract: Approximately 1.1 million, or 13 %, of all TB cases in 2013 were coinfected with HIV, and in some African countries, such as Botswana and Swaziland, 60-80 % of TB cases are coinfected with HIV. Effective therapies for both HIV and TB exist, yet patients presenting with TB and advanced HIV still experience high rates of morbidity and mortality despite initiation of both antitubercular and antiretroviral therapy (ART). Previous reviews and research have focused largely on TB-associated immune reconstitution inflammatory syndrome (TB-IRIS) as a type of complicated outcome on ART in advanced HIV/TB, but recent data indicate that immunologic failure despite suppressive ART is associated with early mortality. In this review, we examine recent findings regarding early mortality in HIV/TB and emerging concepts in the pathophysiology of TB-IRIS, in order to provide an integrated view of factors determining outcomes in coinfected people as well as highlight key needs for future research and therapeutic development.
authors.affiliation: Division of Infectious Diseases, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA, bisson@mail.med.upenn.edu.
authors.forename: Gregory P
authors.initials: GP
authors.lastname: Bisson
authors.forename: Nicola
authors.initials: N
authors.lastname: Zetola
authors.forename: Ronald G
authors.initials: RG
authors.lastname: Collman
mesh_terms: D044966:Anti-Retroviral Agents / Q000627:therapeutic use*; D000995:Antitubercular Agents / Q000627:therapeutic use*; D060085:Coinfection / Q000401:mortality; D015658:HIV Infections / Q000188:drug therapy / Q000401:mortality*; D006801:Humans; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy / Q000401:mortality*
chemical_list: D044966:Anti-Retroviral Agents; D000995:Antitubercular Agents